Pfizer Entered into an Exclusive Four-Year Research Collaboration with Beam to Boost In Vivo Base Editing Programs for Rare Diseases
Shots:
- Beam to receive $300M up front & ~$1.35B in milestone along with royalties on net sales for the licensed program. The companies will share profits, development & commercialization costs in a 65%:35% ratio
- The collaboration combines Pfizer’s expertise in drug development with Beam’s leadership in base editing & mRNA/LNP technologies to advance gene-editing therapies for rare diseases
- Beam gets the right into a co-development & co-commercialization agreement for 1 program & will lead the research activities for 3 undisclosed targets. Pfizer exercises its opt-in license rights for all 3 targets & will lead the development activities, regulatory approvals, and commercialization for each product
Ref: Pfizer | Image: The Wall Street Journal
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com